The Latest Breaking News on Pharma

The healthcare sector is set for robust growth, driven by surging demand for quality treatments, a growing patient base, breakthroughs in biopharma, and supportive policies. Therefore, investors could consider undervalued pharmaceutical stocks like Merck & Co. (MRK), Pfizer (PFE), and Cigna (CI) with significant upside potential. Read more.

Nearly five years after COVID-19, a new analysis by The Associated Press shows that U.S. regulators are struggling to address a massive backlog of uninspected pharmaceutical plants

The lifecycle of AMD's new (but still unannounced) GPU continues, and now we're seeing the low-end version move in shipping manifests.

Meta, Costco and Eli Lilly along with two others are trading near buy points coming out of a week marked by Nvidia earnings.

The weight-loss drugs market could be worth up to $144 billion within six years. And a bevy of pharma stocks could get a lift.

With the rising prevalence of chronic diseases, increasing cell and gene therapies, and rising tech adoption in the biotech industry, the oncology market is booming. Amid this backdrop, investors could consider quality biotech stocks Pyxis Oncology (PYXS), Immatics (IMTX), and Jazz Pharmaceuticals (JAZZ), having significant upside potential. Continue reading.

Galapagos stock surged Monday after the Food and Drug Administration cleared the biotech company to begin testing its cancer drug in people.

Mother tells Maya Oppenheim she was forced into having a hysterectomy which meant she ‘car crashed into menopause’ at the age of 45

AMD's budget-friendly B850 and B840 chipset motherboards will seemingly arrive in 2025, limiting AMD's September launch to its higher-end X-series chipsets.